Chatham Capital Group Inc. Purchases 309 Shares of Johnson & Johnson (NYSE:JNJ)

Chatham Capital Group Inc. lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,194 shares of the company’s stock after acquiring an additional 309 shares during the period. Johnson & Johnson makes up approximately 1.5% of Chatham Capital Group Inc.’s portfolio, making the stock its 13th largest position. Chatham Capital Group Inc.’s holdings in Johnson & Johnson were worth $8,098,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the company. Waterway Wealth Management LLC purchased a new position in Johnson & Johnson in the 1st quarter worth about $822,000. Strata Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson by 219.2% during the first quarter. Strata Wealth Advisors LLC now owns 5,927 shares of the company’s stock valued at $938,000 after purchasing an additional 4,070 shares during the last quarter. Sandy Cove Advisors LLC lifted its position in Johnson & Johnson by 4.4% during the first quarter. Sandy Cove Advisors LLC now owns 5,597 shares of the company’s stock valued at $885,000 after purchasing an additional 238 shares during the period. Trilogy Capital Inc. boosted its holdings in Johnson & Johnson by 91.5% in the first quarter. Trilogy Capital Inc. now owns 4,392 shares of the company’s stock worth $695,000 after purchasing an additional 2,099 shares during the last quarter. Finally, Red Door Wealth Management LLC raised its stake in Johnson & Johnson by 2.0% during the 1st quarter. Red Door Wealth Management LLC now owns 47,322 shares of the company’s stock valued at $7,486,000 after buying an additional 921 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.2 %

NYSE JNJ opened at $146.42 on Tuesday. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The stock’s 50 day moving average is $148.14 and its 200 day moving average is $154.05. The stock has a market cap of $352.39 billion, a PE ratio of 9.13, a P/E/G ratio of 2.43 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. Johnson & Johnson’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.68 earnings per share. Research analysts predict that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a $1.24 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.39%. The ex-dividend date of this dividend was Monday, May 20th. Johnson & Johnson’s payout ratio is currently 30.92%.

Wall Street Analyst Weigh In

Several brokerages recently commented on JNJ. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday. The Goldman Sachs Group began coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target for the company. Bank of America cut their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research report on Monday, June 17th. Finally, HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $174.07.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.